Lattice Biologics (TSXV:LBL.H) Cash And Cash Equivalents : C$0.00 Mil (As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Cash And Cash Equivalents?

Lattice Biologics's quarterly cash and cash equivalents increased from Dec. 2020 (C$0.03 Mil) to Mar. 2021 (C$0.03 Mil) but then stayed the same from Mar. 2021 (C$0.03 Mil) to Jun. 2021 (C$0.00 Mil).

Lattice Biologics's annual cash and cash equivalents increased from Sep. 2018 (C$0.01 Mil) to Sep. 2019 (C$0.02 Mil) and increased from Sep. 2019 (C$0.02 Mil) to Sep. 2020 (C$0.08 Mil).

Lattice Biologics Cash And Cash Equivalents Historical Data

The historical data trend for Lattice Biologics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Cash And Cash Equivalents Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.07

0.02

0.01

0.02

0.08

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.03	0.08	0.03	0.03	-

Lattice Biologics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Lattice Biologics (TSXV:LBL.H) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Lattice Biologics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines